Literature DB >> 23154639

STAT1, STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling drive SOCS3 expression in inactive ulcerative colitis.

Yi Li1, Jasper Deuring, Maikel P Peppelenbosch, Ernst J Kuipers, Colin de Haar, C Janneke van der Woude.   

Abstract

Ulcerative colitis (UC) is a chronic disease associated with long periods of quiescent disease followed by fulminant exacerbation. Imminent relapse in UC is associated with high mucosal expression of suppressor of cytokine signaling 3 (SOCS3); hence, knowledge of the mechanisms driving mucosal SOCS3 expression may provide important clues as to rational therapy. Thus, here we aim to characterize the molecular forces driving SOCS3 expression in the mucosal compartment, focusing on druggable pathways. The colon epithelial cell line Caco-2 was stimulated with interferon (IFN)-γ, interleukin (IL)-4 or prostaglandin E(2) (PGE(2)) to allow correlations between SOCS3 expression with signal transducer and activator of transcription 1 (STAT1), STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling, respectively. The physiological relevance of the findings obtained was assessed by immunohistochemical staining for the activated forms of STAT1, STAT6, protein kinase A (PKA)-Cγ and cAMP response element-binding protein (CREB) in biopsies from inactive UC patients and controls. Stimulation with IFN-γ, IL-4 or PGE(2) induced activation of STAT1, STAT6 and cAMP, respectively, in colonic cells, without any signs of concomitant STAT3 activation. Forced activation of all these signaling pathways was sufficient for SOCS3 expression. Biopsies from patients with inactive UC showed significant increase of phosphorylated STAT1 (p-STAT1) (p < 0.0001), p-STAT6 (p = 0.0001), p-PKA-Cγ (p = 0.0003) and p-CREB (p = 0.0025) expression compared with controls. STAT3-independent SOCS3 induction in inactive UC involves multiple proinflammatory signaling pathways and contradicts the usefulness of pathway-specific antiinflammatory drugs for preventing relapse. Our findings suggest that broad-spectrum antiinflammatory drugs are essential to counteract increases in SOCS3 expression and exacerbation of disease. Our results highlight the multifactorial nature of the factors that cause exacerbation in UC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23154639      PMCID: PMC3533641          DOI: 10.2119/molmed.2012.00277

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  32 in total

Review 1.  Cells, cytokines and inflammatory bowel disease: a clinical perspective.

Authors:  Ian C Roberts-Thomson; James Fon; Wendy Uylaki; Adrian G Cummins; Simon Barry
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-12       Impact factor: 3.869

Review 2.  SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer.

Authors:  Yi Li; Colin de Haar; Maikel P Peppelenbosch; C Janneke van der Woude
Journal:  Cytokine Growth Factor Rev       Date:  2012-05-15       Impact factor: 7.638

3.  Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis.

Authors:  Yi Li; Veerle J A A Nuij; Judith E Baars; Katharina Biermann; Ernst J Kuipers; Maikel P Peppelenbosch; Colin de Haar; C Janneke van der Woude
Journal:  Inflamm Bowel Dis       Date:  2013-01       Impact factor: 5.325

Review 4.  Review article: remission rates achievable by current therapies for inflammatory bowel disease.

Authors:  L Peyrin-Biroulet; M Lémann
Journal:  Aliment Pharmacol Ther       Date:  2011-02-15       Impact factor: 8.171

5.  IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells.

Authors:  Hans A R Bluyssen; M Mehdi Rastmanesh; Chantal Tilburgs; Kim Jie; Sebastiaan Wesseling; Marie-Jose Goumans; Peter Boer; Jaap A Joles; Branko Braam
Journal:  Am J Physiol Cell Physiol       Date:  2010-05-19       Impact factor: 4.249

6.  DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites.

Authors:  G B Ehret; P Reichenbach; U Schindler; C M Horvath; S Fritz; M Nabholz; P Bucher
Journal:  J Biol Chem       Date:  2000-10-26       Impact factor: 5.157

7.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.

Authors:  K Geboes; R Riddell; A Ost; B Jensfelt; T Persson; R Löfberg
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 8.  New insights into the role of STAT3 in IBD.

Authors:  Yi Li; Colin de Haar; Maikel P Peppelenbosch; C Janneke van der Woude
Journal:  Inflamm Bowel Dis       Date:  2011-10-12       Impact factor: 5.325

9.  Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population.

Authors:  Lynnette R Ferguson; Dug Yeo Han; Alan G Fraser; Claudia Huebner; Wen Jiun Lam; Angharad R Morgan; He Duan; Nishi Karunasinghe
Journal:  Mutat Res       Date:  2010-01-28       Impact factor: 2.433

10.  Suppression of tumour-specific CD4⁺ T cells by regulatory T cells is associated with progression of human colorectal cancer.

Authors:  Gareth Betts; Emma Jones; Syed Junaid; Tariq El-Shanawany; Martin Scurr; Paul Mizen; Mayur Kumar; Sion Jones; Brian Rees; Geraint Williams; Awen Gallimore; Andrew Godkin
Journal:  Gut       Date:  2011-12-29       Impact factor: 23.059

View more
  11 in total

1.  The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling.

Authors:  Yingcong Yu; Shujuan Wu; Jianxin Li; Renye Wang; Xupei Xie; Xuefeng Yu; Jianchun Pan; Ying Xu; Liang Zheng
Journal:  Metab Brain Dis       Date:  2014-05-08       Impact factor: 3.584

Review 2.  JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.

Authors:  Azucena Salas; Cristian Hernandez-Rocha; Marjolijn Duijvestein; William Faubion; Dermot McGovern; Severine Vermeire; Stefania Vetrano; Niels Vande Casteele
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-19       Impact factor: 46.802

3.  IL-6/STAT3/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis.

Authors:  Ying-Ying Chen; Zhi-Bin Ma; Hong-Yu Xu; Li-Jun Shi; Dong-Yue Li; Li-Ying Sun; Xun-Hai Yin; Guo-Yin Sang; Dan Xu; Yin-Hua Tang; Xi Wang; Peng Li; Feng Wu; Jin Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

4.  Anti-inflammatory Effects of Herbal Preparations STW5 and STW5-II in Cytokine-Challenged Normal Human Colon Cells.

Authors:  Mathias Schneider; Thomas Efferth; Heba Abdel-Aziz
Journal:  Front Pharmacol       Date:  2016-10-26       Impact factor: 5.810

5.  Downregulation of miR-214-3p May Contribute to Pathogenesis of Ulcerative Colitis via Targeting STAT6.

Authors:  Jin-An Li; Yong-Duo Wang; Kui Wang; Zhen-Lan Wang; Dao-Yong Jia; Bi-Ying Yang; Chang-Bing Xiong
Journal:  Biomed Res Int       Date:  2017-07-02       Impact factor: 3.411

6.  Integrated strategy of differentially expressed genes associated with ulcerative colitis.

Authors:  Juerong Feng; Qian Gao; Qing Liu; Fan Wang; Xue Lin; Qiu Zhao; Jing Liu; Jin Li
Journal:  Mol Med Rep       Date:  2017-09-18       Impact factor: 2.952

Review 7.  Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease.

Authors:  Friederike Cordes; Dirk Foell; John Nik Ding; Georg Varga; Dominik Bettenworth
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

Review 8.  Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models.

Authors:  Sun Young Moon; Kwang Dong Kim; Jiyun Yoo; Jeong-Hyung Lee; Cheol Hwangbo
Journal:  Molecules       Date:  2021-05-10       Impact factor: 4.411

Review 9.  Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer.

Authors:  Sebastian Zundler; Markus F Neurath
Journal:  Vaccines (Basel)       Date:  2016-02-29

10.  The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma.

Authors:  Dorota Pastuszak-Lewandoska; Daria Domańska-Senderowska; Adam Antczak; Jacek Kordiak; Paweł Górski; Karolina H Czarnecka; Monika Migdalska-Sęk; Ewa Nawrot; Justyna M Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.